Related Experiment Video

Updated: Jan 2, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.0K

miR-1305 Inhibits The Progression Of Non-Small Cell Lung Cancer By Regulating MDM2

Yuxing Cai1, Yi Hao2, HaiFeng Ren3

  • 1Department of Respiratory Medicine, Baoji Central Hospital, Baoji, 721008, People's Republic of China.

Cancer Management and Research
|December 7, 2019
PubMed
Abstract

Insights

MicroRNA 1305 (miR-1305) is downregulated in non-small cell lung cancer (NSCLC), inhibiting tumor progression. Restoring miR-1305 suppresses NSCLC growth by targeting MDM2, offering a potential therapeutic strategy.

Area of Science:

  • Molecular Biology
  • Oncology
  • Gene Regulation

Background:

  • MicroRNAs (miRNAs) play a critical role in non-small cell lung cancer (NSCLC) development.
  • The tumor-suppressive function of miR-1305 is known in cancer, but its specific role in NSCLC requires further elucidation.

Purpose of the Study:

  • To investigate the expression and function of miR-1305 in NSCLC.
  • To identify the molecular targets and signaling pathways regulated by miR-1305 in NSCLC.

Main Methods:

  • Quantitative real-time PCR (RT-qPCR) for miR-1305 expression.
  • Cell proliferation, colony formation, and flow cytometry assays to assess cellular effects.
  • Bioinformatic prediction and luciferase reporter assays to identify and validate miR-1305 targets.
  • Western blot analysis for protein expression (MDM2, p53).

Main Results:

  • miR-1305 expression is significantly decreased in NSCLC tissues and cell lines.
  • Downregulation of miR-1305 correlates with metastasis and poor prognosis in NSCLC patients.
  • Overexpression of miR-1305 inhibits NSCLC cell proliferation and migration, and promotes apoptosis.
  • MDM2 was identified as a direct target of miR-1305, with miR-1305 binding to the 3'-UTR of MDM2.
  • miR-1305 reduces MDM2 levels, leading to increased p53 abundance and subsequent suppression of NSCLC progression.

Conclusions:

  • A novel mechanism involving the miR-1305/MDM2/p53 signaling axis in NSCLC progression was identified.
  • miR-1305 demonstrates potential as a therapeutic target for NSCLC treatment.
Keywords:
MDM2NSCLCmiR-1305p53

More Related Videos

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.8K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.5K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K